Genzada Pharmaceuticals Usa, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://genzada.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Trial to Investigate GZ21T in Healthy Volunteers
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Genzada Pharmaceuticals USA, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT06888362
- Locations
- 🇸🇪
CTC (Clinical Trial Consultants) AB, Uppsala, Sweden
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced CancerPancreatic CancerProstate Cancer MetastaticColo-rectal CancerSolid TumorSolid CarcinomaSolid Carcinoma of StomachHead and Neck Squamous Cell CarcinomaBasal Cell CarcinomaCutaneous T-cell Lymphoma
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Genzada Pharmaceuticals USA, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT03775525
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
News
No news found